In this module, Robert M. Rifkin, MD, FACP, and Kenneth G. Saag, MD, MSc, provide their expert answers to your frequently asked questions about biosimilars and their application in clinical practice.
In this module, Sanjiv S. Agarwala, MD, and Alan J. Kivitz, MD, CPI, expand on the application of biosimilars to clinical practice by answering questions submitted by learners.
In this downloadable slideset, Sanjiv S. Agarwala, MD; Alan J. Kivitz, MD, CPI; Robert M. Rifkin, MD, FACP; and Kenneth G. Saag, MD, MSc, provide an overview of biosimilars, a new therapeutic class of drugs.
Biosimilars promise increased access and decreased prices for patients in need of expensive biologics. However, as with any new category of drug, biosimilars face some uncertainties. Here’s my take.
The role of biosimilars in the setting of IBD is growing. Here’s my take on some of the key things you need to consider when using these agents.
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.